Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.
Launched by IPSEN · Nov 14, 2018
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Any subjects from the participating sites (dead or alive) who have received at least one dose of cabozantinib within the ATU program or between 10/12/2016 and 16/02/2018 and for whom the medical file is available
- Exclusion Criteria:
- • Patients alive at study initiation who have not received information notice
- • who have opposed to data collection.
About Ipsen
Ipsen is a global biopharmaceutical group dedicated to innovation and specialty care, focusing on the discovery, development, and commercialization of transformative medicines for patients with serious diseases. With a strong emphasis on oncology, neuroscience, and rare diseases, Ipsen leverages cutting-edge research and advanced technologies to deliver high-quality therapies that address unmet medical needs. Committed to scientific excellence and ethical practices, Ipsen collaborates with healthcare professionals and stakeholders to drive patient-centered solutions and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Ipsen Medical Director
Study Director
Ipsen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials